The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

September 15, 2020

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

September 10, 2020

Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.

September 08, 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

September 05, 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

September 02, 2020

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

September 01, 2020

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

September 01, 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

August 29, 2020

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

August 29, 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

August 27, 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

August 27, 2020

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

August 20, 2020

Neeta Somaiah, MD, discusses ​remaining challenges in soft tissue sarcoma.

August 20, 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

August 19, 2020

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

August 17, 2020

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

August 10, 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

August 05, 2020

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

August 05, 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

August 04, 2020

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

August 03, 2020

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.